Dr. Lal PathLabs Ltd’s fundamental analysis highlights key financial metrics: Market Cap of ₹27,556.21 crore, PE Ratio of 73.5, Debt to Equity of 13.10, and Return on Equity of 19.96%. These indicators reflect the company’s financial health and market valuation.
Dr. Lal Path Labs Ltd Overview
Dr. Lal PathLabs Ltd is an Indian company engaged in providing diagnostic and related healthcare tests and services. It operates in the healthcare sector, specializing in pathological investigations across various branches of medical diagnostics.
The company is listed on both the NSE and BSE. With a market capitalization of ₹27,556.21 crore, it’s currently 1.48% away from its 52-week high and 70.34% away from its 52-week low.
Dr. Lal Path Labs Ltd Financial Results
Dr. Lal Path Labs reported revenue growth, with sales increasing to ₹2,227 crores in FY 24 from ₹2,017 crores in FY 23. Operating profit and EPS improved, while equity remained steady. Reserves grew to ₹1,715 crores, enhancing return on net worth.
1. Revenue Trend: Sales increased to ₹2,227 crores in FY 24 from ₹2,017 crores in FY 23, indicating a growth in revenue.
2. Equity and Liabilities: Equity capital remained steady at ₹83 crores, with total liabilities increasing slightly to ₹2,456 crores.
3. Profitability: Operating profit rose to ₹609 crores, with an OPM of 26.54%, up from 23.79% in FY 23.
4. Earnings per Share (EPS): EPS increased to ₹42.85 in FY 24, compared to ₹28.65 in FY 23, showing improved earnings.
5. Return on Net Worth (RoNW): RoNW improved as reserves increased to ₹1,715 crores, reflecting strong profitability.
Dr. Lal Path Labs Ltd Financial Analysis
| FY 24 | FY 23 | FY 22 | |
| Sales | 2,227 | 2,017 | 2,087 |
| Expenses | 1,617 | 1,527 | 1,527 |
| Operating Profit | 609 | 490 | 561 |
| OPM % | 26.54 | 23.79 | 26.2 |
| Other Income | 69 | 42 | 53 |
| EBITDA | 678 | 532 | 613 |
| Interest | 29 | 38 | 30 |
| Depreciation | 144 | 150 | 108 |
| Profit Before Tax | 505 | 344 | 475 |
| Tax % | 28 | 30 | 26 |
| Net Profit | 362 | 241 | 350 |
| EPS | 42.85 | 28.65 | 41.37 |
| Dividend Payout % | 56.01 | 41.88 | 29.01 |
* Consolidated Figures in Rs. Crores
Dr. Lal Path Labs Limited Company Metrics
Dr. Lal PathLabs Ltd’s company metrics include a market capitalization of ₹27,556.21 crore, a book value per share of ₹222, and a face value of ₹10. With a debt-to-equity ratio of 13.10, a return on equity of 19.96%, and a 0.55% dividend yield, these figures underscore the company’s financial position and investment profile.
Market Capitalization:
Market Capitalization represents the total market value of Dr. Lal PathLabs’ outstanding shares, amounting to ₹27,556.21 crore.
Book Value:
The book value per share of Dr. Lal PathLabs is ₹222, indicating the value of the company’s net assets divided by its outstanding shares.
Face Value:
The face value of Dr. Lal PathLabs’ shares is ₹10, which is the original cost of the shares as stated on the certificate.
Asset Turnover Ratio:
The asset turnover ratio of 0.95 measures how efficiently Dr. Lal PathLabs uses its assets to generate revenue.
Total Debt:
The total debt of ₹246.93 crore represents the sum of all short-term and long-term debt obligations of Dr. Lal PathLabs.
Return on Equity (ROE):
The ROE of 19.96% measures Dr. Lal PathLabs’ profitability in generating income from its equity investments.
EBITDA (Q):
The quarterly EBITDA of ₹190.6 crore represents Dr. Lal PathLabs’ earnings before interest, taxes, depreciation, and amortization.
Dividend Yield:
The dividend yield of 0.55% shows the annual dividend payment as a percentage of Dr. Lal PathLabs’ current share price, indicating the return on investment from dividends alone.
Dr. Lal Path Labs Ltd Stock Performance
Dr. Lal PathLabs Ltd has demonstrated a 40.4% return on investment (ROI) over 1 year, a negative 4.86% return over 3 years, and a 19.3% return over 5 years. This reflects short-term growth with moderate long-term performance.
| Period | Return on Investment (%) |
| 1 Year | 40.4 |
| 3 Years | -4.86 |
| 5 Years | 19.3 |
Example: If an investor had invested ₹1,000 in Dr. Lal PathLabs Ltd stock:
1 year ago, their investment would be worth ₹1,404.
3 years ago, their investment would have decreased to ₹951.40.
5 years ago, their investment would have grown to ₹1,193.
Dr. Lal Path Labs Peer Comparison
Dr. Lal PathLabs Ltd, with a market cap of ₹28,031 Crores, a P/E ratio of 73.48, and a 1-year return of 40.4%, compares well with peers like Apollo Hospitals (39.73% return) and Max Healthcare (85.27% return), but shows a stronger ROE at 20.36%.
| Name | CMP Rs. | Mar Cap Rs.Cr. | P/E | ROE % | EPS 12M Rs. | 1Yr return % | ROCE % | Div Yld % |
| Apollo Hospitals | 7122 | 102422.76 | 98.86 | 13.67 | 72.14 | 39.73 | 15.55 | 0.22 |
| Max Healthcare | 1030.4 | 100177.99 | 95.06 | 13.37 | 10.84 | 85.27 | 16 | 0.15 |
| Fortis Health. | 594.95 | 44965.07 | 70.04 | 7.85 | 8.65 | 79.09 | 10.34 | 0.17 |
| Global Health | 1092.95 | 29379.02 | 60.91 | 17.93 | 17.97 | 56.86 | 19.32 | 0 |
| Dr. Lal Pathlabs | 3349.95 | 28031.06 | 73.48 | 20.36 | 45.7 | 40.4 | 25.17 | 0.72 |
| Narayana Hrudaya | 1225.6 | 25046.46 | 31.05 | 31.43 | 39.47 | 15.4 | 26.54 | 0.33 |
| Poly Medicure | 2376.2 | 24072.74 | 89.29 | 19.08 | 28.1 | 72.36 | 23.62 | 0.13 |
Dr. Lal Path Labs Shareholding Pattern
Dr. Lal Path Labs Ltd’s shareholding pattern for June 2024 shows that promoters hold 54.60%, unchanged from March and December 2023. FIIs decreased slightly to 25.43%, while DIIs increased to 12.71%. Retail and others’ stake decreased to 7.25% from 9.56% in March.
| All values in % | Jun-24 | Mar-24 | Dec-23 |
| Promoters | 54.60 | 54.60 | 54.60 |
| FII | 25.43 | 26.15 | 25.36 |
| DII | 12.71 | 9.69 | 9.56 |
| Retail & others | 7.25 | 9.56 | 10.49 |
Dr. Lal Path Labs Ltd History
Dr. Lal PathLabs Limited is a leading diagnostic and healthcare service provider in India. The company specializes in running laboratories for various pathological investigations, covering a wide range of medical disciplines including biochemistry, hematology, histopathology, microbiology, and immunology.
The company offers an extensive range of diagnostic tests catering to numerous medical conditions. These include tests for allergies, diabetes, viral infections, heart diseases, cancer, and many other health issues. This comprehensive test portfolio allows Dr. Lal PathLabs to serve diverse healthcare needs.
Dr. Lal PathLabs has expanded its operations through subsidiaries such as Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited. This expansion strategy has helped the company to strengthen its presence in the diagnostic services market across different regions.
How To Invest In Dr. Lal Path Labs Ltd Share?
To invest in Dr. Lal PathLabs shares, open a demat account with Alice Blue. Research the company’s fundamentals, financial performance, and position in the diagnostic services sector. Analyze historical stock data and compare it with industry peers.
Determine your investment strategy based on your financial goals and risk tolerance. Consider factors such as the company’s market share, technological advancements in diagnostics, and healthcare sector trends. Decide on the investment amount and timing.
Place your order through the broker’s platform. Regularly monitor your investment, staying updated on company news, quarterly results, and healthcare industry trends. Consider seeking advice from a financial advisor for personalized guidance and to ensure your investment aligns with your overall portfolio strategy.
Dr. Lal Path Labs Limited Fundamental Analysis FAQs
Dr. Lal PathLabs Ltd’s fundamental analysis reveals a Market Cap of ₹27,556.21 crore, PE Ratio of 73.5, Debt to Equity of 13.10, and Return on Equity of 19.96%. These metrics provide insights into the company’s financial health, profitability, and market valuation.
Dr. Lal PathLabs’ market capitalization is ₹27,556.21 crore. This figure represents the total value of the company’s outstanding shares in the stock market, calculated by multiplying the current stock price by the number of outstanding shares.
Dr. Lal PathLabs Limited is an Indian diagnostic and healthcare service provider. The company specializes in pathological investigations and offers a wide range of diagnostic tests across various medical disciplines, serving patients and healthcare providers across India.
Dr. Lal PathLabs is owned by its shareholders, with the founder Dr. Arvind Lal, and his family holding a significant stake. As a publicly listed company, ownership is distributed among various institutional and individual investors through stock market participation.
The main shareholders of Dr. Lal PathLabs Ltd include the promoter group (Dr. Arvind Lal and family), along with institutional investors and public shareholders. For the most current and accurate information on major shareholders, refer to the company’s latest shareholding pattern disclosure.
Dr. Lal PathLabs operates in the healthcare industry, specifically in the diagnostic services sector. The company specializes in providing a wide range of pathological tests and related healthcare services, playing a crucial role in medical diagnosis and patient care.
To invest in Dr. Lal PathLabs shares, open a demat account with Alice Blue. Research the company’s performance and healthcare sector trends. Decide on your investment strategy. Place your order through the broker’s platform. Regularly monitor your investment, staying informed about market conditions. Consider seeking financial advice for personalized guidance.
Determining if Dr. Lal PathLabs is overvalued or undervalued requires analyzing its financials, growth prospects, industry position, and peer comparison. Consider factors like PE ratio, future earnings potential, and healthcare sector trends. Consult recent analyst reports for expert opinions on the company’s valuation.
We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
